ESR1 and breast carcinoma: In light of the above, it has been suggested that the development of ER subtype specific ligands may herald the arrival of a new generation of estrogen analogues that may present a novel treatment for post-menopausal symptoms, which in addition, may prevent or decrease the occurrence of breast cancer [44,48,49].